Format
Sort by

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 957

1.

[Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation].

Murachi K, Kumagai T, Masuda T, Nakanishi T, Tanaka S, Tajima K, Takebe Y, Oda T.

Hinyokika Kiyo. 2016 Jun;62(6):295-306. Japanese.

PMID:
27452492
2.

Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.

Zhong X, Lim EA, Hershman DL, Moinpour CM, Unger J, Lee SM.

J Oncol Pract. 2016 Mar;12(3):e270-80, 245-6. doi: 10.1200/JOP.2015.006106.

PMID:
26907453
3.

Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.

Blanchard P, Faivre L, Lesaunier F, Salem N, Mesgouez-Nebout N, Deniau-Alexandre E, Rolland F, Ferrero JM, Houédé N, Mourey L, Théodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Davin JL, Habibian M, Culine S, Laplanche A, Fizazi K.

Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):85-92. doi: 10.1016/j.ijrobp.2015.09.020.

PMID:
26576711
4.

Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.

Inoue T, Ogura K, Kawakita M, Tsukino H, Akamatsu S, Yamasaki T, Matsui Y, Segawa T, Sugino Y, Kamoto T, Kamba T, Tanaka S, Ogawa O.

Clin Genitourin Cancer. 2016 Feb;14(1):e9-e17. doi: 10.1016/j.clgc.2015.08.008.

PMID:
26433627
5.

A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.

Rosenthal SA, Hunt D, Sartor AO, Pienta KJ, Gomella L, Grignon D, Rajan R, Kerlin KJ, Jones CU, Dobelbower M, Shipley WU, Zeitzer K, Hamstra DA, Donavanik V, Rotman M, Hartford AC, Michalski J, Seider M, Kim H, Kuban DA, Moughan J, Sandler H.

Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):294-302. doi: 10.1016/j.ijrobp.2015.05.024.

6.

Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity.

Mitsui Y, Arichi N, Hiraki M, Harada Y, Yasumoto H, Shiina H.

Urol J. 2015 Jul 1;12(3):2165-72.

7.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X.

PMID:
26028518
8.

Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.

Petrioli R, Roviello G, Fiaschi AI, Laera L, Bianco V, Ponchietti R, Barbanti G, Francini E.

Clin Genitourin Cancer. 2015 Oct;13(5):441-6. doi: 10.1016/j.clgc.2015.03.004.

PMID:
25920994
9.

Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.

Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y.

Int J Clin Oncol. 2015 Oct;20(5):1018-25. doi: 10.1007/s10147-015-0802-y.

PMID:
25681879
10.

Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis.

Koie T, Ohyama C, Yamamoto H, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Yoneyama T, Tobisawa Y, Aoki M, Takai Y.

World J Surg Oncol. 2014 Apr 30;12:134. doi: 10.1186/1477-7819-12-134.

11.

Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series.

Aurilio G, Graffeo R, Bagnardi V, Nolè F, Adamoli L, Pagani O, Gallerani E, Ferrari B, Pruneri G, Goldhirsch A.

Int J Clin Oncol. 2015 Feb;20(1):90-4. doi: 10.1007/s10147-014-0694-2.

PMID:
24722887
12.

Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.

Silberstein JL, Poon SA, Sjoberg DD, Maschino AC, Vickers AJ, Bernie A, Konety BR, Kelly WK, Eastham JA.

BJU Int. 2015 Jul;116(1):50-6. doi: 10.1111/bju.12676.

13.

Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.

Zhang C, Jing T, Wang F, Gao X, Xu C, Sun Y.

Actas Urol Esp. 2014 Apr;38(3):184-91. doi: 10.1016/j.acuro.2013.07.010. English, Spanish.

PMID:
24507454
14.

Chemotherapy and its evolving role in the management of advanced prostate cancer.

Schweizer MT, Antonarakis ES.

Asian J Androl. 2014 May-Jun;16(3):334-40. doi: 10.4103/1008-682X.122593. Review.

15.

Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy.

Hayakawa N, Matsumoto K, Sato A, Sakamoto H, Ezaki T, Maeda T, Ninomiya A, Nakamura S.

Int Urol Nephrol. 2014 Jun;46(6):1123-9. doi: 10.1007/s11255-013-0634-5.

PMID:
24356920
16.

US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.

D'Amico AV.

J Clin Oncol. 2014 Feb 1;32(4):362-4. doi: 10.1200/JCO.2013.53.9528. No abstract available.

PMID:
24344221
17.

Estramustine-induced suicidal erythrocyte death.

Bissinger R, Modicano P, Frauenfeld L, Lang E, Jacobi J, Faggio C, Lang F.

Cell Physiol Biochem. 2013;32(5):1426-36.

18.

[Hormonal treatment in prostate cancer].

Bastide C, Bruyère F, Karsenty G, Guy L, Rozet F.

Prog Urol. 2013 Nov;23(15):1246-57. doi: 10.1016/j.purol.2013.08.325. Review. French.

PMID:
24183083
19.
20.

Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.

Matsumoto K, Tanaka N, Hayakawa N, Ezaki T, Suzuki K, Maeda T, Ninomiya A, Nakamura S.

Med Oncol. 2013 Dec;30(4):717. doi: 10.1007/s12032-013-0717-2.

PMID:
24005812
Items per page

Supplemental Content

Support Center